SCHEMBL6231050

SCHEMBL6231050

O=C(NOC1CCCCO1)C1(S(=O)(=O)c2ccc3nc(-c4ccsc4)sc3c2)CCOCC1

nearest known ligand 0.34

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.34
KMT2A Q03164 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MAPK1 P28482 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MMP2 P08253 12/20 0.33
MMP13 P45452 12/20 0.33
MMP8 P22894 8/20 0.33
MMP1 P03956 8/20 0.33
MMP9 P14780 7/20 0.33
MMP3 P08254 6/20 0.33
MMP14 P50281 6/20 0.33
CLK1 P49759 1/20 0.33
ILK Q13418 1/20 0.33
MMP7 P09237 1/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8312860 0.88 RORC (0.37) ALDH1A1KMT2AHSD17B10SMN1; SMN2MMP2
SCHEMBL6276528 0.87 ALDH1A1 (0.37) ALDH1A1KMT2AHSD17B10MAPK1SMN1; SMN2
SCHEMBL6234746 0.87 MMP2 (0.44) ALDH1A1KMT2AHSD17B10MMP2MMP13
SCHEMBL6267605 0.87 MMP13 (0.37) ALDH1A1KMT2AHSD17B10SMN1; SMN2MMP2
SCHEMBL6278357 0.86 MMP8 (0.46) MMP2MMP13MMP8MMP1MMP9
SCHEMBL6231944 0.86 ALDH1A1 (0.39) ALDH1A1KMT2AHSD17B10MAPK1SMN1; SMN2
SCHEMBL6230548 0.85 MMP13 (0.41) ALDH1A1KMT2AHSD17B10SMN1; SMN2MMP2
SCHEMBL6229096 0.85 MMP2 (0.44) ALDH1A1KMT2AHSD17B10SMN1; SMN2MMP2
SCHEMBL6230523 0.85 MMP2 (0.46) ALDH1A1KMT2AHSD17B10MAPK1SMN1; SMN2
SCHEMBL6228597 0.85 MMP13 (0.36) ALDH1A1KMT2AHSD17B10MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1565459-A2 HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS Pharmacia Corporation (US) 2005-08-24 EP disclosed
US-20040142979-A1 Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors PHARMACIA CORPORATION 2004-07-22 US disclosed
WO-2004048368-A2 HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS PHARMACIA CORPORATION (US) 2004-06-10 WO disclosed
WO-2004048368-A2 HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS PHARMACIA CORPORATION (US) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142979-A1 Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors MMP3, MMP13, MMP10 ALDH1A1 1789/4885KMT2A 1113/4885HSD17B10 526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.